- Home
- ELBM vs ITRM Comparison
ELBM vs ITRM Comparison
Compare ELBM & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- ITRM
- Stock Information
- Founded
- ELBM 2011
- ITRM 2015
- Country
- ELBM Canada
- ITRM Ireland
- Employees
- ELBM N/A
- ITRM N/A
- Industry
- ELBM Industrial Machinery/Components
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- ITRM Health Care
- Exchange
- ELBM Nasdaq
- ITRM Nasdaq
- Market Cap
- ELBM 29.6M
- ITRM 24.7M
- IPO Year
- ELBM N/A
- ITRM 2018
- Fundamental
- Price
- ELBM $0.52
- ITRM $1.36
- Analyst Decision
- ELBM Strong Buy
- ITRM Strong Buy
- Analyst Count
- ELBM 1
- ITRM 1
- Target Price
- ELBM $1.40
- ITRM $5.00
- AVG Volume (30 Days)
- ELBM 53.0K
- ITRM 7.1M
- Earning Date
- ELBM 11-19-2024
- ITRM 11-14-2024
- Dividend Yield
- ELBM N/A
- ITRM N/A
- EPS Growth
- ELBM N/A
- ITRM N/A
- EPS
- ELBM N/A
- ITRM N/A
- Revenue
- ELBM N/A
- ITRM N/A
- Revenue This Year
- ELBM N/A
- ITRM N/A
- Revenue Next Year
- ELBM $1,630.56
- ITRM N/A
- P/E Ratio
- ELBM N/A
- ITRM N/A
- Revenue Growth
- ELBM N/A
- ITRM N/A
- 52 Week Low
- ELBM $0.26
- ITRM $0.81
- 52 Week High
- ELBM $0.75
- ITRM $2.50
- Technical
- Relative Strength Index (RSI)
- ELBM 41.55
- ITRM 53.86
- Support Level
- ELBM $0.52
- ITRM $1.16
- Resistance Level
- ELBM $0.58
- ITRM $1.61
- Average True Range (ATR)
- ELBM 0.03
- ITRM 0.16
- MACD
- ELBM -0.00
- ITRM 0.00
- Stochastic Oscillator
- ELBM 21.82
- ITRM 29.41
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.